Abstract Library

#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?

Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merola E

Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,

Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,

#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs

Introduction: NETs overexpress somatostatin receptors (SSTRs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cives M

Authors: Mandriani B, Cives M, Pelle' E, Quaresmini D, Ramello M,

Keywords: CAR T cells, adoptive cellular immunotherapy, NETs,

#2753 Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, El-Haddad G, Pelle E, Strosberg J,

Keywords: PRRT, Lutetium-dotatate, Bowel obstruction, Peritoneal carcinomatosis, Steroids,

#2037 Stromal Immune Contexture Predicts Disease-Free Survival in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)

Introduction: Stromal Immune Contexture (SIC) helps predict prognosis in solid Tumors (T) but has been poorly investigated in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). We tested whether GEP-NENs profiling for adaptive immunity-related SIC markers, as well as inflammatory (COX2),EMT [Beta-catenin (B-cat)] and oncogenic pathway signaling (pS6) markers,could improve Ki67 and/or MO-based prediction of OS and DFS.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Milione M

Authors: Milione M, Miceli R, Pellegrinelli A, Spaggiari P, Tagliabue G,

Keywords: Neuroendocrine, Ki-67, Morphology, Immune contexture, PDL1, Beta-Catenin,

#2033 Ki-67 and Presence of Liver Metastases Predicts Progression in Pancreatic Neuroendocrine Neoplasms (pNENs)

Introduction: In pancreatic neuroendocrine neoplasms (pNENs), size ≤20 mm and Ki-67 ≤2% suggest indolent behavior, but no factor alone can predict prognosis.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Milione M

Authors: Milione M, Maisonneuv P, Pellegrinelli A, Spaggiari P, Centonze G,

Keywords: Ki-67, Prognosis, Pancreas, Neuroendocrine, size, liver metastases, Biopsy, Surgical,